Castle Biosciences received approval from the New York State Department of Health for its AdvanceAD-Tx test, a non-invasive gene expression profile designed to guide systemic therapy for patients aged 12 and older with moderate-to-severe atopic dermatitis. This test helps clinicians select the most effective treatment by analyzing a patient's disease biology from a skin sample, improving personalized care and potentially reducing ineffective treatment cycles. The approval expands access to this precision medicine tool in New York, supporting better outcomes for millions affected by this chronic skin condition. Castle now holds NY approval for all tests in its dermatology and ophthalmology portfolios, enhancing its diagnostic reach.
Coinbase has introduced a new fixed-rate borrowing option for USDC loans secured by bitcoin collateral through its integration with Morpho Midnight on the Base network. This allows users to access liquidity without selling their bitcoin, offering tra...
The S&P 500 reached new all-time highs during the second quarter of 2026, continuing a strong rally that has characterized much of the year. However, the index experienced some pullback heading into September due to rising oil prices and Treasury yie...
On September 22, 2026, 21Shares launched the first physically backed Zcash (ZEC) ETP on Euronext Paris and Amsterdam, allowing investors to trade ZEC without managing private keys. This product carries higher fees (2.5%) due to the technical complexi...
Hyperliquid's market liquidity reached a record $8.8 billion, surpassing last October's peak, driven by increased trading as Bitcoin recovered above $85K. This surge doubled Hyperliquid's daily revenue to $3 million in Q3, with a tripling in mid-Augu...
U.S. investment-grade corporate bonds gained in the second quarter, with a fund outperforming its benchmark, the Bloomberg U.S. Corporate Bond Index. The outperformance was driven by careful individual security selection and sector allocation, partic...
